Genor Biopharma Holdings Limited (67N0) AI Stock Analysis

0 Followers

Genor Biopharma Holdings Limited

(Frankfurt:67N0)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

2025 Profitability InflectionThe sharp 2025 shift to meaningful revenue and solid operating profitability indicates the company has recently converted its biologics activities into an earnings-generating business. If maintained, this higher-margin base can support reinvestment in drug development, manufacturing, and commercialization over the next several quarters.

Negative Factors

Unproven Earnings DurabilityThe 2025 earnings improvement follows a long period of inconsistent results, including several years of losses and periods with zero reported revenue. That history makes it difficult to establish a dependable earnings trend, so the company must demonstrate that the recent commercial and profit step-up is repeatable.

Genor Biopharma Holdings Limited (67N0) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 360.41M
Dividend Yield: ―
Average Volume (3M): 8,060
Price to Earnings (P/E): 4.2
Beta (1Y): 0.34
Revenue Growth: 1307.13%
EPS Growth: 587.04%
Country: Germany
Employees: 1,499
Sector: General
Sector Strength: 55
Industry: Biotechnology

Genor Biopharma Holdings Limited Business Overview & Revenue Model

Company Description

Edding Genor Group Holdings Limited operates as a biopharmaceutical enterprise, concentrating its efforts on the research, development, and commercialization of therapeutic agents for oncology and autoimmune disorders, both within China and globally....

Genor Biopharma Holdings Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

DE:67N0 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
HK:2181	51Neutral	HKD 1.81B	20.33	48.25%	―	88.38%	―
HK:1167	48Neutral	HKD 3.78B	6.29	47.76%	―	286.20%	―
HK:1541	44Neutral	HKD 1.21B	-4.85	-32.32%	―	28.93%	27.27%
HK:6996	44Neutral	HKD 1.82B	29.99	6.51%	―	605.95%	―
HK:3681	43Neutral	HKD 1.38B	-6.42	-41.81%	―	―	-4.24%

* General Sector Average

Performance Comparison

DE:67N0 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:67N0	Genor Biopharma Holdings Limited	0.17	-0.17	-49.71%
HK:6996	Antengene Corporation Limited	2.82	-2.05	-42.09%
HK:1167	Jacobio Pharmaceuticals Group Co., Ltd.	4.80	-2.33	-32.61%
HK:2181	Mabpharm Limited	0.49	-0.03	-5.77%
HK:3681	SinoMab Bioscience Ltd.	1.00	-0.80	-44.44%
HK:1541	ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H	3.02	-4.89	-61.82%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Genor Biopharma Holdings Limited AI Stock Analysis